Filing summary
Entity and period: The request metadata names ACCENDRA HEALTH INC, but the supplied filing is Owens & Minor, Inc. (NYSE: OMI), Form 10-K for the fiscal year ended December 31, 2020. It reports annual results, not standalone fourth-quarter results; the filing text does not provide a clear Q4 income statement. Unless stated otherwise, figures below are for continuing operations.
Business context
Owens & Minor operates two segments: Global Solutions, which distributes medical and surgical supplies and provides related services, and Global Products, which manufactures and sources medical products, including personal protective equipment (PPE). In June 2020, the company sold its European logistics business, Movianto, for $133 million. Its results are presented as discontinued operations.
Key financial metrics
| Metric | 2020 | 2019 |
|---|---|---|
| Net revenue | $8.480 billion | $9.211 billion |
| Gross margin | $1.281 billion; 15.10% of revenue | $1.128 billion; 12.25% of revenue |
| Operating income | $204.1 million; 2.41% of revenue | $73.2 million; 0.79% of revenue |
| Income (loss) from continuing operations | $88.1 million; $1.39 per diluted share | $(22.6) million; $(0.37) per diluted share |
| Net income (loss), including discontinued operations | $29.9 million | $(62.4) million |
| Cash from operating activities | $339.2 million | $166.1 million |
| Capital expenditures | $59.2 million | $52.2 million |
| Cash and cash equivalents at year-end | $83.1 million | $67.0 million |
| Total debt at year-end | $1.026 billion | $1.560 billion |
Operating cash flow and investing and financing cash flows include discontinued operations. Cash and cash equivalents exclude restricted cash; cash, cash equivalents and restricted cash totaled $134.5 million at year-end 2020. The company reported $283 million available under its revolving credit facility and compliance with debt covenants at year-end. Total equity was $712.1 million, versus $462.2 million in 2019. The annual cash dividend was $0.01 per share.
Changes versus prior year
- Revenue decreased 7.9%. Global Solutions revenue declined 12.5% to $7.212 billion, reflecting prior customer non-renewals and fewer elective procedures during COVID-19.
- Global Products revenue increased 26.2% to $1.810 billion, supported by PPE demand. Segment operating income rose to $259.9 million from $65.1 million; Global Solutions operating income fell to $30.9 million from $83.6 million.
- Gross margin increased by 2.85 percentage points, with management citing product mix, productivity and Global Products operating efficiencies. DS&A expense rose 1.8% to $1.041 billion and increased as a share of revenue to 12.28%.
- Operating cash flow increased to $339.2 million. Working-capital movements included higher accounts payable, inventory and receivables.
- Debt declined by approximately $534 million, following equity issuance, asset-sale proceeds, debt repayments and note repurchases. The company issued shares for approximately $190 million net proceeds.
Outlook, risks and unusual items
- Management said it could not predict the pandemic’s timing or full future financial impact. PPE demand and productivity gains may not persist as conditions normalize, while reduced elective procedures, supply disruptions, additional operating costs and changing customer payment patterns remain risks. No quantified earnings or revenue guidance is provided in the supplied filing text.
- The Movianto sale resulted in a $65.5 million loss and a $58.2 million after-tax discontinued-operations loss in 2020. A final working-capital adjustment could produce a benefit of up to $41.5 million; none was recognized at year-end.
- Global Products benefited from pandemic-related PPE demand, favorable mix and operating efficiencies. The company expanded production capacity and reported more than 12 billion PPE units delivered since January 2020. Government contracts and initiatives included an HHS N-95 mask contract and a Defense Department technology investment agreement of up to $30 million; approximately $27.0 million had been spent and $20.8 million reimbursed by year-end.
- Debt and refinancing are material risks. The company had approximately $1.0 billion of secured debt, including $245 million of 2024 Notes; those notes’ maturity interacts with a springing maturity provision in the Term B Loan. Variable-rate borrowings expose results to interest-rate changes.
- The IRS proposed adjustments concerning 2015 and 2016 transfer pricing. The company disputes the position and says it believes its reserve is adequate, but states an adverse outcome could materially affect financial position, results or cash flows.
- Other risks include concentration in GPO relationships and suppliers, competitive pricing pressure, volatile polypropylene and nitrile costs, regulatory and product-liability exposure, and operational, cyber and supply-chain disruptions. The filing reports ordinary-course litigation and says pending matters are not expected to have a material adverse effect based on current knowledge.
- Management and the auditor reported effective internal control over financial reporting; the auditor issued an unqualified opinion on the financial statements.
Important facts for investors to verify
- Confirm the issuer: the supplied document is Owens & Minor, not ACCENDRA HEALTH INC.
- Review whether PPE demand, manufacturing output and related margins remain sustainable as pandemic conditions and government programs change.
- Track Global Solutions recovery, customer renewals and elective-procedure volumes against the 2020 decline.
- Assess debt maturities, refinancing options, covenant headroom, available liquidity and the springing maturity provision.
- Follow the Movianto working-capital adjustment and the outcome of the IRS transfer-pricing dispute.
- Separate continuing-operations performance from discontinued-operations losses and note that reported cash flows include discontinued operations.